Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ION582 in Children and Adults With Angelman Syndrome
NCT07782827Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 3 trial of obudanersen in Angelman syndrome (AS), sponsored by Ionis Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
obudanersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT07782827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782827.